期刊文献+

TFAP2E通过激活TGF-β信号通路促进肝癌细胞的增殖和迁移 被引量:1

TFAP2E promotes hepatocellular carcinoma cell proliferation and migration by activating TGF-β signaling pathway
原文传递
导出
摘要 目的探讨转录因子激活蛋白2E(TFAP2E)对人肝癌细胞系HepG2和HCC-LM3细胞增殖和迁移能力的影响及其可能的分子机制。方法在人肝癌细胞系HepG2和HCC-LM3中使用慢病毒包装方法转染入TFAP2E过表达的重组质粒,筛选得到稳定过表达TFAP2E的肝癌细胞系。转染小干扰RNA(siRNA)抑制人肝癌细胞系HepG2和HCC-LM3中TFAP2E的表达。Western印迹法在肝癌细胞系中检测TFAP2E蛋白的表达水平,以验证TFAP2E的过表达和敲低效果。Cell Counting Kit-8(CCK-8)法评价TFAP2E对肝癌细胞系增殖能力的影响。Transwell实验检测TFAP2E对肝癌细胞系迁移能力的影响。NetworkAnalyst方法鉴定TFAP2E高、低表达组间的差异表达基因;基于上述的显著差异表达基因,利用Enrichr软件进行通路富集分析,以揭示TFAP2E在肝癌细胞中的作用机制。采用Log-rank检验比较TFAP2E的表达水平对肝癌患者生存期的影响。结果过表达TFAP2E可显著促进HepG2和HCC-LM3细胞的增殖和迁移能力,而敲低TFAP2E可显著抑制HepG2和HCC-LM3细胞的增殖和迁移能力。生物信息学分析提示TFAP2E可能参与TGF-β信号通路的调控。随后的实验证实,在HepG2细胞系中过表达TFAP2E可显著上调SMAD2的磷酸化水平,而敲低TFAP2E则显著下调SMAD2的磷酸化水平。临床相关性分析显示,TFAP2E在肝癌组织中的表达显著高于癌旁组织,且TFAP2E的高表达与肝癌患者的不良预后显著相关。结论TFAP2E可能通过促进TGF-β信号通路的激活,促进肝癌细胞的增殖和迁移,从而发挥癌基因的功能。 Objective To assess the effects of transcription factor activator protein 2E(TFAP2E) on cell proliferation and migration of hepatocellular carcinoma(HCC) cell lines HepG2 and HCC-LM3,and the underlying molecular mechanism.Methods The TFAP2E overexpression recombinant plasmid was transfected into the HepG2 and HCC-LM3 cells,respectively,by lentivirus packaging.The small interfering RNA(siRNA) was used to knock-down the endogenous TFAP2E in HepG2 and HCC-LM3 cells.Western blotting assay was used to detect the protein levels of TFAP2E in HCC cells.Cell Counting Kit-8(CCK-8) and Transwell assays were used to assess the abilities of HCC cells to proliferate and migrate,respectively.Network Analyst was used to evaluate the differentially expressed genes between the high and low TFAP2E expression groups,and pathway enrichment analysis was performed by Enrichr to unveil the molecular mechanisms of TFAP2E in HCC cells.Log-rank test was used to assess the overall survival difference between the HCC patients with high and low expression levels of TFAP2E.Results Overexpression of TFAP2E could significantly promote the HepG2 and HCC-LM3 cell proliferation and migration,whereas knockdown of TFAP2E significantly inhibited the HepG2 and HCC-LM3 cell proliferation and migration.Bioinformatics analysis revealed that TFAP2E might be involved in the TGF-βsignaling pathway.Consistently,overexpression of TFAP2E significantly upregulated p-SMAD2 levels in HepG2 cells,whereas knockdown of TFAP2E led to the downregulation of p-SMAD2 levels.Of note,TFAP2E was significantly upregulated in HCC tissues compared to the non-tumor liver tissues,and the higher expression levels of TFAP2E were significantly associated with poor outcomes of HCC patients.Conclusion TFAP2E might play oncogenic roles in HCC cells by activating the TGF-β signaling pathway.
作者 金亮 周光明 王亚会 周钢桥 JIN Liang;ZHOU Guang ming;WANG Ya hui;ZHOU Gang qiao(The State Key Lab of Proteomics,National Center for Protein Sciences,Institute of Radiation Medicine,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100850,China)
出处 《军事医学》 CAS 北大核心 2019年第10期739-746,共8页 Military Medical Sciences
基金 国家自然科学基金(91440206).
关键词 肝癌 转录因子激活蛋白2E 细胞增殖 细胞迁移 转化生长因子Β 信号通路 hepatocellular carcinoma TFAP2E cell proliferation cell migration TGF-β signaling pathway
  • 相关文献

参考文献4

二级参考文献123

  • 1Liu, Xiao-Fang,Kong, Fan-Min,Xu, Zheng,Yu, Shao-Ping,Sun, Fu-Bo,Zhang, Cui-Sheng,Huang, Qing-Xian,Zhou, Xian-Ting,Song, Zhan-Wen.Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma[J].Hepatobiliary & Pancreatic Diseases International,2007,6(4):407-411. 被引量:9
  • 2杨少辉,戴冬秋.胃癌DAPK基因甲基化的初步研究[J].中华肿瘤防治杂志,2007,14(2):93-95. 被引量:7
  • 3Chun-Feng Meng Xin-Jiang Zhu Guo Peng Dong-Qiu Dai.Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines[J].World Journal of Gastroenterology,2007,13(46):6166-6171. 被引量:27
  • 4Steel JL, Nadeau K, Olek M, Carr BI. Preliminary results of anindividually tailored psychosocial intervention for patients withadvanced hepatobiliary carcinoma. J Psychosoc Oncol 2007; 25:19-42 [PMID: 19341012 DOI: 10.1300/J077v25n03_02].
  • 5Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis:from genes to environment. Nat Rev Cancer 2006; 6: 674-687[PMID: 16929323 DOI: 10.1038/nrc1934].
  • 6Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebasedmanagement of hepatocellular carcinoma--an updatedanalysis of randomized controlled trials. Aliment PharmacolTher 2006; 23: 1535-1547 [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x].
  • 7Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A,Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L.Liver transplantation for the treatment of small hepatocellularcarcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104].
  • 8Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A,Ascher NL, Roberts JP. Liver transplantation for hepatocellularcarcinoma: expansion of the tumor size limits does not adverselyimpact survival. Hepatology 2001; 33: 1394-1403 [PMID:11391528 DOI: 10.1053/jhep.2001.24563].
  • 9Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW,Lee SK. HCC in living donor liver transplantation: can we expandthe Milan criteria- Dig Dis 2007; 25: 313-319 [PMID: 17960066DOI: 10.1159/000106911].
  • 10Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K,Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansionof selection criteria for patients with hepatocellular carcinomain living donor liver transplantation. Liver Transpl 2007; 13:1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281].

共引文献117

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部